Development of a radioiodinated apoptosis-inducing ligand, rhTRAIL, and a radiolabelled agonist TRAIL receptor antibody for clinical imaging studies

British Journal of Pharmacology

Volumn 165, Issue 7, 2012, Pages 2203-2212

  Duiker, E W ^a   Dijkers, E C F ^a   Lambers Heerspink, H ^a   De Jong, S ^a   Van Der Zee, A G J ^a   Jager, P L ^a   Kosterink, J G W ^a   De Vries, E G E ^a   Lub De Hooge, M N ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

molecular imaging; radiopharmaceuticals; rhTRAIL; TRAIL receptor monoclonal antibody; TRAIL R1

Indexed keywords

DEATH RECEPTOR 4; MAPATUMUMAB IN 111; RADIOPHARMACEUTICAL AGENT; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND I 125; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; COLON CANCER; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG PURITY; DRUG STABILITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; KIDNEY CLEARANCE; MALE; MOUSE; NONHUMAN; PLASMA CLEARANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOACTIVITY; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; HUMANS; INDIUM RADIOISOTOPES; IODINE RADIOISOTOPES; ISOTOPE LABELING; MALE; MICE; MICE, NUDE; RADIOPHARMACEUTICALS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECOMBINANT PROTEINS; TISSUE DISTRIBUTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84858229586     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01718.x     Document Type: Article

References (35)

1. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, et al,. (1999). Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 104: 155-162.
2. Chen XP, He SQ, Wang HP, Zhao YZ, Zhang WG, (2003). Expression of TNF-related apoptosis-inducing Ligand receptors and antitumor effects of TNF-related apoptosis-inducing Ligand in human hepatocellular carcinoma. World J Gastroenterol 9: 2433-2440.
3. Clarke K, Lee FT, Brechbiel MW, Smyth FE, Old LJ, Scott AM, (2000). In vivo biodistribution of a humanised anti-Lewis Y monoclonal antibody (hu3S193) in MCF-7 xenografted BALB/c nude mice. Cancer Res 60: 4804-4811.
4. Debatin KM, Krammer PH, (2004). Death receptors in chemotherapy and cancer. Oncogene 23: 2950-2966. (Pubitemid 38638855)
5. Dijkers EC, Kosterink JG, Rademaker AP, Perk LR, Van Dongen GA, Bart J, et al,. (2009). Development and characterization of clinical-grade 89Zr-trastuzumab for HER2/neu immunoPET imaging. J Nucl Med 50: 974-981.
6. Duiker EW, Mom CH, de Jong S, Willemse PHB, Gietema JA, Van Der Zee AGJ, et al,. (2006). The clinical trail of TRAIL. Eur J Cancer 42: 2233-2240. (Pubitemid 44307615)
7. Duncan JR, Welch MJ, (1993). Intracellular metabolism of indium-111-DTPA-labeled receptor targeted proteins. J Nucl Med 34: 1728-1738. (Pubitemid 23295386)
8. Van Geelen CM, de Vries EG, Le TK, Van Weeghel RP, de Jong S, (2003). Differential modulation of the TRAIL receptors and the CD95 receptor in colon carcinoma cell lines. Br J Cancer 89: 363-373. (Pubitemid 36976328)
9. Gong J, Yang D, Kohanim S, Humphreys R, Broemeling L, Kurzrock R, (2006). Novel in vivo imaging shows up-regulation of death receptors by paclitaxel and correlates with enhanced antitumor effects of receptor agonist antibodies. Mol Cancer Ther 12: 2991-3000. (Pubitemid 46092040)
10. Held J, Schulze-Osthoff K, (2001). Potential and caveats of TRAIL in cancer therapy. Drug Resist Updat 4: 243-252. (Pubitemid 34456378)
11. Herbst RS, Mendelson DS, Ebbinghaus S, Gordon MS, O'Dwyer P, Lieberman G, et al,. (2006). A phase I safety and pharmacokinetic (PK) study of recombinant Apo2L/TRAIL, an apoptosis-inducing protein in patients with advanced cancer. J Clin Oncol 24: 3013.
12. Holoch PA, Griffith TS, (2009). TNF-related apoptosis-inducing ligand (TRAIL): a new path to anti-cancer therapies. Eur J Pharmacol 625: 63-72.
13. Horak P, Pils D, Kaider A, Pinter A, Elandt K, Sax C, et al,. (2005). Perturbation of the tumor necrosis factor-related apoptosis-inducing ligand cascade in ovarian cancer: overexpression of FLIPL and deregulation of the functional receptors DR4 and DR5. Clin Cancer Res 11: 8585-8591. (Pubitemid 43005904)
14. Kelley SK, Harris LA, Xie D, DeForge L, Totpal K, Bussiere J, et al,. (2001). Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. J Pharmacol Exp Ther 299: 31-38. (Pubitemid 32905115)
15. Kohlhaas SL, Craxton A, Sun XM, Pinkoski MJ, Cohen GM, (2007). Receptor-mediated endocytosis is not required for TRAIL-induced apoptosis. J Biol Chem 282: 12831-12841.
16. Koornstra JJ, Jalving M, Rijcken FE, Westra J, Zwart N, Hollema H, et al,. (2005). Expression of tumour necrosis factor-related apoptosis-inducing ligand death receptors in sporadic and hereditary colorectal tumours: potential targets for apoptosis induction. Eur J Cancer 41: 1195-1202. (Pubitemid 40725579)
17. LeBlanc HN, Ashkenazi A, (2003). Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ 10: 66-75. (Pubitemid 36511833)
18. Leong S, Cohen RB, Gustafson DL, Langer CJ, Camidge DR, Padavic K, et al,. (2009). Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study. J Clin Oncol 26: 4413-4421.
19. Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn PA Jr, (1984). Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods 72: 77-89. (Pubitemid 14091996)
20. Ling J, Herbst RS, Mendelson DS, Eckhardt SG, O'Dwyer P, Ebbinghaus S, et al,. (2006). Apo2L/TRAIL pharmacokinetics in a phase Ia trial in advanced cancer and lymphoma. J Clin Oncol Proc Am Soc Clin Oncol 24: 3047.
21. Lub-de Hooge MN, Kosterink JG, Perik PJ, Nijnuis H, Tran L, Bart J, et al,. (2004). Preclinical characterisation of 111In-DTPA-trastuzumab. Br J Pharmacol 143: 99-106.
22. McLarty K, Cornelissen B, Scollard DA, Done SJ, Chun K, Reilly RM, (2009). Associations between the uptake of 111In-DTPA-trastuzumab, HER2 density and response to trastuzumab (Herceptin) in athymic mice bearing subcutaneous human tumour xenografts. Eur J Nucl Med Mol Imaging 36: 81-93.
23. Marini P, Denzinger S, Schiller D, Kauder S, Welz S, Humphreys R, et al,. (2006). Combined treatment of colorectal tumours with agonistic TRAIL receptor antibodies HGS-ETR1 and HGS-ETR2 and radiotherapy: enhanced effects in vitro and dose-dependent growth delay in vivo. Oncogene 25: 5145-5154. (Pubitemid 44285983)
24. Mom CH, Verweij J, Oldenhuis CN, Gietema JA, Fox NL, Miceli RL, et al,. (2009). Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: a phase I study. Clin Cancer Res 17: 5584-5590.
25. Pegram MD, Konecny G, Slamon DJ, (2000). The molecular and cellular biology of HER2/neu gene amplification/overexpression and the clinical development of herceptin (trastuzumab) therapy for breast cancer. Cancer Treat Res 103: 57-75.
26. Press OW, Shan D, Howell-Clark J, Eary J, Appelbaum FR, Matthews D, et al,. (1996). Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells. Cancer Res 56: 2123-2129. (Pubitemid 26119913)
27. Pukac L, Kanakaraj P, Humphreys R, Alderson R, Bloom M, Sung C, et al,. (2005). HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo. Br J Cancer 92: 1430-1441. (Pubitemid 40705010)
28. Reesink-Peters N, Hougardy BM, Van den Heuvel FA, Ten Hoor KA, Hollema H, Boezen HM, et al,. (2005). Death receptors and ligands in cervical carcinogenesis: an immunohistochemical study. Gynecol Oncol 96: 705-713. (Pubitemid 40255490)
29. Schneider P, Olson D, Tardivel A, Browning B, Lugovskoy A, Gong D, et al,. (2003). Identification of a new murine tumor necrosis factor receptor locus that contains two novel murine receptors for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J Biol Chem 278: 5444-5454. (Pubitemid 36801061)
30. Spierings DC, de Vries EG, Vellenga E, Van den Heuvel FA, Koornstra JJ, Wesseling J, et al,. (2004). Tissue distribution of the death ligand TRAIL and its receptors. J Histochem Cytochem 52: 821-831. (Pubitemid 38703137)
31. Tolcher AW, Mita M, Meropol NJ, von Mehren M, Patnaik A, Padavic K, et al,. (2007). Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. J Clin Oncol 25: 1390-1395. (Pubitemid 46706887)
32. Truneh A, Sharma S, Silverman C, Khandekar S, Reddy MP, Deen KC, et al,. (2000). Temperature-sensitive differential affinity of TRAIL for its receptors. DR5 is the highest affinity receptor. J Biol Chem 275: 23319-23325. (Pubitemid 30646233)
33. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, et al,. (1995). Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3: 673-682. (Pubitemid 26091143)
34. Wu GS, Burns TF, Zhan Y, Alnemri ES, El Deiry WS, (1999). Molecular cloning and functional analysis of the mouse homologue of the KILLER/DR5 tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor. Cancer Res 59: 2770-2775. (Pubitemid 29283105)
35. Xiang H, Nguyen CB, Kelley SK, Dybdal N, Escandon E, (2004). Tissue distribution, stability, and pharmacokinetics of Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand in human colon carcinoma COLO205 tumor-bearing nude mice. Drug Metab Dispos 32: 1230-1238. (Pubitemid 39410906)